Impact of amyloid and cardiometabolic risk factors on prognostic capacity of plasma neurofilament light chain for neurodegeneration

Table 1 Demographic and clinical characteristics of non-demented participants at baseline

	Overall participants (n = 720)
Age (years)	72.1 (7.00)
Sex, female	351 (48.8%)
Education (years)	16.4 (2.60)
Race/ethnicity, non-Hispanic White	663 (92.1%)
Cognitive status
CU	279 (38.8%)
MCI	441 (61.3%)
APOE ε4 allele count
0	425 (59.0%)
1	243 (33.8%)
2	52 (7.2%)
History of ever smoking	136 (18.9%)
History of alcohol abuse	17 (2.4%)
SGDS	1.40 (1.42)
Follow-up period (months)	62.5 (35.9)
Florbetapir PET SUVR	1.18 (0.216)
Cerebral Aβ status ( +)^a	341 (47.4%)
Hypertension	478 (66.4%)
Well-controlled hypertension^b	104 (21.8% of hypertension)
DM	114 (15.8%)
Impaired kidney function	39 (5.4%)
Obesity^c	186 (25.8%)
ADAS-Cog score	12.5 (6.60)
Hippocampal volume (mm³)	6490 (854)
WMH volume (mm³)	6520 (9430)
Plasma NfL (pg/mL)	36.8 (20.3)

Data are presented as mean (standard deviation) for continuous variables and n (%) for categorical variables
Abbreviations: Aβ amyloid-β, ADAS-Cog Alzheimer's Disease Assessment Scale-Cognitive subscale, APOE apolipoprotein E, BMI body mass index, CU cognitively unimpaired, DM diabetes mellitus, MCI mild cognitive impairment, NfL neurofilament light chain, PET positron emission tomography, SGDS Short form of Geriatric Depression Scale, SUVR standard uptake value ratio, WMH white matter hyperintensity
^aFlorbetapir PET SUVR 1.11 or over was regarded as cerebral Aβ status ( +)
^bSystolic blood pressure under 120 mmHg, in combination with history of hypertension or concurrent anti-hypertensive medication, was defined as well-controlled hypertension
^cBMI 30 kg/m² or over was defined as obesity

ISSN: 1758-9193